Literature DB >> 9628276

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.

M F Kong1, T A Stubbs, P King, I A Macdonald, J E Lambourne, P E Blackshaw, A C Perkins, R B Tattersall.   

Abstract

In a previous study we have shown that an intravenous infusion of pramlintide (an analogue of human amylin) delayed gastric emptying, but the dose of pramlintide was supraphysiological in relation to the amylin response to food in non-diabetic subjects. The purpose of this study was to examine the dose response relationship of subcutaneous injections of pramlintide on gastric emptying and to determine whether administration of the drug before one meal has an impact on the subsequent meal. Eleven men with insulin-dependent diabetes mellitus were studied in a double-blind, randomised, four-way crossover design. None had autonomic neuropathy. Euglycaemia was maintained overnight before the study day. At -30 min the patients self-injected their usual morning insulin and at -15 min they injected the study drug (either placebo or 30, 60 or 90 microg pramlintide) subcutaneously. At 0 min they ate a standard meal consisting of a pancake, labelled with 99mTc, and a milkshake containing 3-ortho-methylglucose (3-OMG). Gastric emptying images were obtained for the next 8 h. At 240 min the subjects ate a similar meal, but on this occasion the pancake was labelled with (111)In. All three doses of pramlintide delayed emptying of the solid component of the first meal (p < 0.004) with no significant difference between the drug doses. There were no differences between placebo and pramlintide after the second meal. All three doses of pramlintide resulted in a prolongation in the time to peak plasma 3-OMG level (p < 0.0001) after the first meal but there was no difference after the second meal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628276     DOI: 10.1007/s001250050949

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

Authors:  Jing Fang; Cornelia B Landersdorfer; Brenda Cirincione; William J Jusko
Journal:  AAPS J       Date:  2012-10-02       Impact factor: 4.009

2.  Development of proteolytically stable N-methylated peptide inhibitors of aggregation of the amylin peptide implicated in type 2 diabetes.

Authors:  Idira Obasse; Mark Taylor; Nigel J Fullwood; David Allsop
Journal:  Interface Focus       Date:  2017-10-20       Impact factor: 3.906

Review 3.  Amylin-mediated control of glycemia, energy balance, and cognition.

Authors:  Elizabeth G Mietlicki-Baase
Journal:  Physiol Behav       Date:  2016-02-27

Review 4.  Control of energy homeostasis by amylin.

Authors:  Thomas A Lutz
Journal:  Cell Mol Life Sci       Date:  2011-12-23       Impact factor: 9.261

Review 5.  Adjunct therapy for type 1 diabetes mellitus.

Authors:  Harold E Lebovitz
Journal:  Nat Rev Endocrinol       Date:  2010-04-20       Impact factor: 43.330

Review 6.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

7.  In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.

Authors:  Francesco Micheletto; Chiara Dalla Man; Orville Kolterman; Elaine Chiquette; Kathrin Herrmann; Jörg Schirra; Boris Kovatchev; Claudio Cobelli
Journal:  Diabetes Technol Ther       Date:  2013-07-18       Impact factor: 6.118

8.  Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes.

Authors:  T M Davis; F Daly; J P Walsh; K F Ilett; J P Beilby; L J Dusci; P H Barrett
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

9.  A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.

Authors:  Charrise M Ramkissoon; Brian Aufderheide; B Wayne Bequette; Cesar C Palerm
Journal:  J Diabetes Sci Technol       Date:  2014-02-09

10.  Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.

Authors:  Gina Ryan; Tim A Briscoe; Lynette Jobe
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.